^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6)

    i
    Other names: MAP3K6, Mitogen-Activated Protein Kinase Kinase Kinase 6, MAPKKK6, MEKK6, ASK2, Apoptosis Signal-Regulating Kinase 2, Apoptosis Signal Regulating Kinase 2
    10ms
    Effects of Benzo[a]Pyrene Exposure on Lung Cancer: A Mechanistic Study of Epigenetic m6A Levels and YTHDF1. (PubMed, Toxics)
    The acquisition and deletion of miR-139/145-5p, along with luciferase reporter gene assays, demonstrated that miR-139-5p can target YTHDF1. Therefore, we conclude that YTHDF1 regulates CDK6 and MAP3K6 through m6A in B[a]P-induced HBE-P35 and A549 cells, providing a potential target for lung cancer treatment.
    Journal
    |
    CDK6 (Cyclin-dependent kinase 6) • MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6) • MIR139 (MicroRNA 139) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1)
    12ms
    Germline variants in CDKN2A wild-type melanoma prone families. (PubMed, Mol Oncol)
    In particular, XPCL48F was found in 8 indexes; thus, the allele fraction (0.07) was significantly higher than in comparable healthy populations (0.02-0.03; P-values from 0.007 to 0.014). In conclusion, we found that several melanoma-prone families have pathogenic variants in genes not usually linked to melanoma.
    Journal • BRCA Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MSH2 (MutS Homolog 2) • CHEK2 (Checkpoint kinase 2) • MRE11A (MRE11 homolog, double strand break repair nuclease) • MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6)
    1year
    Exploring MAP3K genes in gastric cancer: biomarkers, tumor microenvironment dynamics, and chemotherapy resistance. (PubMed, Hereditas)
    This comprehensive assessment provides valuable insights into the role of MAP3K genes in GC, offering avenues for further research and therapeutic exploration.
    Journal
    |
    MAP3K10 (Mitogen-Activated Protein Kinase Kinase Kinase 10) • MIR200B (MicroRNA 200b) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • MAP3K14 (Mitogen-Activated Protein Kinase Kinase Kinase 14) • MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11) • MAP3K7 (Mitogen-Activated Protein Kinase Kinase Kinase 7) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    almost2years
    Salidroside inhibited the proliferation of gastric cancer cells through up-regulating tumor suppressor miR-1343-3p and down-regulating MAP3K6/MMP24 signal molecules. (PubMed, Cancer Biol Ther)
    miRNAs are expressed differentially in gastric cancer cells after salidroside treatment, playing important roles in regulating proliferation and metastasis. Salidroside may suppress the growth of gastric cancer by up-regulating the expression of the tumor suppressor miR-1343-3p and down-regulating the expression of MAP3K6 and MMP24 signal molecules.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6) • MIR134 (MicroRNA 134)
    over3years
    Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma. (PubMed, Biomark Res)
    We have identified a 3-gene signature (EPHA5, BCL6, and ERBB2) that is predictive of response to neoadjuvant chemoradiotherapy and a separate prognostic 9-gene classifier that predicts survival outcomes. These panels provide significant potential for personalized management of locally advanced esophageal cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ARID1A (AT-rich interaction domain 1A) • BCL6 (B-cell CLL/lymphoma 6) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CSF3R (Colony Stimulating Factor 3 Receptor) • GATA2 (GATA Binding Protein 2) • ETS1 (ETS Proto-Oncogene 1) • EPHA5 (EPH Receptor A5) • MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6)
    |
    HER-2 mutation • EPHA5 mutation
    |
    carboplatin • paclitaxel
    over3years
    Genomic Landscape of Mixed-Phenotype Acute Leukemia. (PubMed, Int J Mol Sci)
    Finally, we show that those patients that received stem cell transplant had a better overall survival. Our findings support the need to genomically profile MPAL cases to exploit opportunities for targeted therapies in this orphan disease with dismal prognosis.
    Journal
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • WT1 (WT1 Transcription Factor) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6)
    |
    TP53 mutation • FLT3-ITD mutation • KMT2D mutation
    almost4years
    Organophosphate flame retardants induce oxidative stress and Chop/Caspase 3-related apoptosis via Sod1/p53/Map3k6/Fkbp5 in NCI-1975 cells. (PubMed, Sci Total Environ)
    Six genes associated with oxidative stress and apoptosis were upregulated dramatically compared with the control, demonstrating OPFRs induced Chop/Caspase 3-related apoptosis by activating Sod1/p53/Map3k6/Fkbp5 expression in NCI-H1975 cells. This is the first study to investigate cytotoxicity and related mechanism on commonly-used OPFRs in NCI-H1975 cells.
    Journal
    |
    CASP3 (Caspase 3) • MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6) • FKBP5 (FKBP Prolyl Isomerase 5)
    |
    FKBP5 expression
    over4years
    [VIRTUAL] Novel Predictive and Prognostic Gene Signatures for Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma (ASTRO 2021)
    Materials/ We assembled a cohort of 34 patients with locally advanced esophageal adenocarcinoma, with the majority (21) receiving concurrent chemoradiotherapy with carboplatin/paclitaxel. We have identified a 3-gene signature (EPHA5, BCL6 and ERBB2) that is predictive of response to neoadjuvant therapy and a separate 9 gene classifier which prognosticates for survival outcomes. These provide significant potential for personalized management of locally advanced esophageal cancer.
    Gene Signature
    |
    HER-2 (Human epidermal growth factor receptor 2) • EML4 (EMAP Like 4) • ARID1A (AT-rich interaction domain 1A) • BCL6 (B-cell CLL/lymphoma 6) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • NOTCH2 (Notch 2) • CSF3R (Colony Stimulating Factor 3 Receptor) • MSH3 (MutS Homolog 3) • GATA2 (GATA Binding Protein 2) • ETS1 (ETS Proto-Oncogene 1) • EPHA5 (EPH Receptor A5) • MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6) • RECQL4( RecQ Like Helicase 4) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • PCLO (Piccolo Presynaptic Cytomatrix Protein)
    |
    HER-2 mutation • MSH3 mutation • EPHA5 mutation
    |
    carboplatin • paclitaxel
    over4years
    Novel Predictive and Prognostic Gene Signatures for Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma. (PubMed, Int J Radiat Oncol Biol Phys)
    We have identified a 3-gene signature (EPHA5, BCL6 and ERBB2) that is predictive of response to neoadjuvant therapy and a separate 9 gene classifier which prognosticates for survival outcomes. These provide significant potential for personalized management of locally advanced esophageal cancer.
    Journal • Gene Signature
    |
    HER-2 (Human epidermal growth factor receptor 2) • EML4 (EMAP Like 4) • ARID1A (AT-rich interaction domain 1A) • BCL6 (B-cell CLL/lymphoma 6) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • NOTCH2 (Notch 2) • CSF3R (Colony Stimulating Factor 3 Receptor) • MSH3 (MutS Homolog 3) • GATA2 (GATA Binding Protein 2) • ETS1 (ETS Proto-Oncogene 1) • EPHA5 (EPH Receptor A5) • MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6) • RECQL4( RecQ Like Helicase 4) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • PCLO (Piccolo Presynaptic Cytomatrix Protein)
    |
    HER-2 mutation • MSH3 mutation • EPHA5 mutation
    |
    carboplatin • paclitaxel